Put Options

18 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$28.84 - $41.15 $245,140 - $349,775
8,500 Added 57.43%
23,300 $671,000
Q2 2024

Aug 14, 2024

SELL
$38.07 - $59.71 $403,542 - $632,926
-10,600 Reduced 41.73%
14,800 $567,000
Q1 2024

May 15, 2024

SELL
$55.39 - $72.47 $60,929 - $79,717
-1,100 Reduced 4.15%
25,400 $1.49 Million
Q4 2023

Feb 14, 2024

BUY
$37.14 - $64.82 $497,676 - $868,587
13,400 Added 102.29%
26,500 $1.59 Million
Q3 2023

Nov 14, 2023

BUY
$23.65 - $89.22 $23,650 - $89,220
1,000 Added 8.26%
13,100 $498,000
Q2 2023

Aug 14, 2023

BUY
$76.68 - $93.31 $253,044 - $307,923
3,300 Added 37.5%
12,100 $1.1 Million
Q1 2023

May 15, 2023

SELL
$46.59 - $66.96 $396,015 - $569,160
-8,500 Reduced 49.13%
8,800 $580,000
Q4 2022

Feb 14, 2023

BUY
$43.24 - $61.04 $155,664 - $219,744
3,600 Added 26.28%
17,300 $894,000
Q3 2022

Nov 14, 2022

SELL
$44.76 - $69.66 $264,084 - $410,994
-5,900 Reduced 30.1%
13,700 $936,000
Q2 2022

Aug 08, 2022

SELL
$35.07 - $59.21 $14,028 - $23,684
-400 Reduced 2.0%
19,600 $886,000
Q1 2022

May 16, 2022

BUY
$35.46 - $54.12 $709,200 - $1.08 Million
20,000 New
20,000 $1.02 Million
Q4 2021

Feb 14, 2022

SELL
$30.74 - $49.16 $1.49 Million - $2.39 Million
-48,600 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$31.4 - $69.84 $1.35 Million - $3 Million
43,000 Added 767.86%
48,600 $1.6 Million
Q2 2021

Aug 16, 2021

BUY
$40.9 - $64.9 $229,040 - $363,440
5,600 New
5,600 $354,000
Q3 2020

Nov 16, 2020

SELL
$25.89 - $33.65 $147,573 - $191,805
-5,700 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$24.8 - $38.49 $116,560 - $180,903
-4,700 Reduced 45.19%
5,700 $186,000
Q1 2020

May 15, 2020

BUY
$17.91 - $44.33 $137,907 - $341,341
7,700 Added 285.19%
10,400 $279,000
Q4 2019

Feb 14, 2020

BUY
$22.1 - $30.8 $59,670 - $83,160
2,700 New
2,700 $83,000

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.64B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Walleye Trading LLC Portfolio

Follow Walleye Trading LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Trading LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Trading LLC with notifications on news.